| DB ID | MyCo_1165 |
| Title | (1-->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia |
| Year | 1996 |
| PMID | 8991635 |
| Fungal Diseases involved | Pneumocystis carinii pneumonia |
| Associated Medical Condition | HIV-AIDS |
| Genus | Pneumocystis |
| Species | carinii |
| Organism | Pneumocystis carinii |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | Eight BALFs were obtained consecutively (July1993 to April 1994) from patients with AIDS and suspected lung diseases at the Hospital of the Institute of Medical Science, University of Tokyo, after obtaining informed consent. |
| Cohort No. | 8 |
| Age Group | None |
| P Value | p<0.05 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | BDG detection kit (G test; Seikagaku Corporation) |
| ELISA kits | BDG detection kit (G test; Seikagaku Corporation) |
| Assay Data | None |
| Validation Techniques used | BDG G test |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
